Drug Discovery & DDS– category –
-
Beyond the Liver: Engineered LNPs Achieve Precision Cardiac Delivery for SCD1 Inhibitor Aramchol
PR Newswire Israel Overview Galmed, in collaboration with Barcode Nanotech, has developed a groundbreaking lipid nanoparticle (LNP) formulation that precisely redirects its SCD1 inhibitor, Aramchol, from liver hepatocytes to cardiac musc... -
Alcimed Analyzes Brain Drug Delivery Barriers and Breakthroughs: Receptor-Mediated Transcytosis and LIFU as Key Enablers
Alcimed France Overview Brain drug delivery is one of modern medicine's most complex challenges due to multiple physiological barriers, notably the blood-brain barrier (BBB), which severely restricts most therapeutic molecules from enter... -
Samsung Biologics Acquires PolyPeptide in All-Cash Offer: Accelerating Multi-Modality Strategy and Global Network Expansion
PR Newswire South Korea Overview Samsung Biologics announced an all-cash offer to acquire PolyPeptide, accelerating its multi-modality strategy and expanding its global manufacturing network across the U.S., Europe, and India. This acqui... -
Focused Ultrasound Blood-Brain Barrier Opening: Remote Metabolic Response Discovered in Primate Brain Raises Clinical Application Challenges
PubMed (National Library of Medicine) USA Overview Low-intensity focused ultrasound (LIFU) is a promising technology for blood-brain barrier (BBB) opening for drug delivery, yet a study in non-human primate models revealed unexpected rem... -
FDA Approval a TPD Turning Point? Maria Soloveychik Cautions Single Molecule Success Doesn’t Guarantee All Targets
Drug Discovery Online USA Overview Maria Soloveychik acknowledges the FDA approval of a bivalent degrader as a crucial 'proof point' for the Targeted Protein Degradation (TPD) field but warns that this single molecular success does not n... -
Oral GLP-1 Market Shift: Foundayo (orforglipron) Gains FDA Approval After Oral Wegovy, Demonstrating Dosing Convenience Advantage
GoodRx Health USA Overview The oral GLP-1 receptor agonist market sees a new entrant as Foundayo (orforglipron) received FDA approval on April 1, 2026, becoming the second oral GLP-1 therapy after oral Wegovy (semaglutide). Foundayo offe... -
Verseon Champions Physics-Based Molecular Design to Transcend AI’s Training Data in Drug Discovery
Endpoints News USA Overview Verseon asserts that physics-based molecular design can reach chemical spaces beyond the limitations of traditional screening and generative AI training data, opening untapped drug discovery realms. Their Deep... -
FDA Approves Dato-DXd (Datroway) for Metastatic Triple-Negative Breast Cancer based on Phase III TROPION-Breast02 Trial
Cancer Network USA Overview The U.S. FDA has approved datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1/PD-L1 immune check... -
BeOne Medicines Invests $300M in New Jersey Manufacturing Expansion, Boosting Biologic, Small Molecule, and ADC Production
Fierce Pharma USA Overview BeOne Medicines announced a $300 million investment to significantly expand its manufacturing facility in New Jersey. The Hopewell campus, opened in 2024, will evolve into a fully integrated manufacturing hub, ... -
EMD Serono’s Investigational Enpatoran Granted FDA Breakthrough Therapy Designation for Active Cutaneous Lupus
Lupus Foundation of America USA Overview EMD Serono's investigational drug enpatoran has received Breakthrough Therapy Designation from the U.S. FDA for the treatment of systemic lupus erythematosus (SLE) with active cutaneous manifestat...
